Dublin, March 10, 2026 (GLOBE NEWSWIRE) -- The "Hylenex Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets.com's offering. The ...

Teclistamab plus daratumumab and hyaluronidase-fihj is approved for relapsed or refractory MM after one prior line of therapy, including a proteasome inhibitor and immunomodulatory agent.

Silver Spring, Maryland Saturday, March 7, 2026, 11:00 Hrs [IST] ...

The Citizens Life Sciences Conference 2026 March 11, 2026 10:45 AM EDTCompany ParticipantsHelen Torley - President, ...

Johnson & Johnson , a worldwide leader in multiple myeloma therapies, today announced that the U.S. Food and Drug ...

Leerink Global Healthcare Conference 2026 March 10, 2026 1:00 PM EDTCompany ParticipantsHelen Torley - President, ...

Learn more about whether Halozyme Therapeutics, Inc. or Tango Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

FDA approval based on Phase 3 data demonstrating statistically significant improvements in progression-free survival and overall survival versus standard of care regimens ...

The FDA has approved teclistamab (Tecvayli) daratumumab and hyaluronidase-fihj (Darzalex Faspro) for the treatment of ...

As NAD+ injections and IV drips trend from TikTok to the Kardashians, the science of longevity remains a work in progress. Explore the benefits, side effects, and the debate between oral precursors ...

Long-lasting treatment suppresses HIV in people with mental illness and other conditions that make it challenging to adhere to standard treatments.

Susvimo is an FDA-approved eye implant for diabetic macular edema that may reduce monthly injections to just two treatments a year while maintaining vision outcomes.